Silexion Therapeutics Ltd.
NASDAQ: SLXNW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ilan Hadar
- Employees
- 11
- Headquarters
- Jerusalem, Israel
- IPO year
- 2024
- Market cap
- $14.1K
- Website
- https://silexion.com
Loading SLXNW…
Loading profile data…Frequently asked questions about SLXNW
What does Silexion Therapeutics Ltd. (SLXNW) do?
Silexion Therapeutics LTD is a biopharmaceutical company focused on the discovery and development of RNA interference (RNAi)-based therapies and their delivery systems, specifically targeting aggressive solid tumors. The firm utilizes its proprietary LODER delivery platform for the treatment of these malignant growths. Its pipeline features SiG1...
Where does SLXNW trade?
Silexion Therapeutics Ltd. (SLXNW) trades on the NASDAQ Global Market.
What sector is SLXNW in?
Silexion Therapeutics Ltd. (SLXNW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Silexion Therapeutics Ltd.?
Ilan Hadar is the chief executive officer of Silexion Therapeutics Ltd. (SLXNW).
Where is Silexion Therapeutics Ltd. headquartered?
Silexion Therapeutics Ltd. is headquartered in Israel.
Does SLXNW pay a dividend?
Silexion Therapeutics Ltd. (SLXNW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SLXNW go public?
Silexion Therapeutics Ltd. (SLXNW) completed its initial public offering in 2024.